Berggren MI - Search Results

1

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Ihle NT, Paine-Murrieta G, Berggren MI, Baker A, Tate WR, Wipf P, Abraham RT, Kirkpatrick DL, Powis G. Ihle NT, et al. Among authors: berggren mi. Mol Cancer Ther. 2005 Sep;4(9):1349-57. doi: 10.1158/1535-7163.MCT-05-0149. Mol Cancer Ther. 2005. PMID: 16170026 Free PMC article.

2

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.

Ihle NT, Williams R, Chow S, Chew W, Berggren MI, Paine-Murrieta G, Minion DJ, Halter RJ, Wipf P, Abraham R, Kirkpatrick L, Powis G. Ihle NT, et al. Among authors: berggren mi. Mol Cancer Ther. 2004 Jul;3(7):763-72. Mol Cancer Ther. 2004. PMID: 15252137

3

Discovery of a novel class of AKT pleckstrin homology domain inhibitors.

Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ. Mahadevan D, et al. Mol Cancer Ther. 2008 Sep;7(9):2621-32. doi: 10.1158/1535-7163.MCT-07-2276. Mol Cancer Ther. 2008. PMID: 18790745 Free PMC article.

4

Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.

Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G. Meuillet EJ, et al. Mol Cancer Ther. 2003 Apr;2(4):389-99. Mol Cancer Ther. 2003. PMID: 12700283

5

Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis.

Nonn L, Berggren M, Powis G. Nonn L, et al. Mol Cancer Res. 2003 Jul;1(9):682-9. Mol Cancer Res. 2003. PMID: 12861054

6

Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.

Berggren MI, Gallegos A, Dressler LA, Modest EJ, Powis G. Berggren MI, et al. Cancer Res. 1993 Sep 15;53(18):4297-302. Cancer Res. 1993. PMID: 8395981

7

Selenium and the thioredoxin redox system: effects on cell growth and death.

Powis G, Gasdaska JR, Gasdaska PY, Berggren M, Kirkpatrick DL, Engman L, Cotgreave IA, Angulo M, Baker A. Powis G, et al. Oncol Res. 1997;9(6-7):303-12. Oncol Res. 1997. PMID: 9406236 Review.

8

The thioredoxin/thioredoxin reductase redox system and control of cell growth.

Powis G, Oblong JE, Gasdaska PY, Berggren M, Hill SR, Kirkpatrick DL. Powis G, et al. Oncol Res. 1994;6(10-11):539-44. Oncol Res. 1994. PMID: 7620223

9

Novel quinone antiproliferative inhibitors of phosphatidylinositol-3-kinase.

Frew T, Powis G, Berggren M, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Hudson C, Gruszecka-Kowalik E, Burgess EM, et al. Frew T, et al. Anticancer Drug Des. 1995 Jun;10(4):347-59. Anticancer Drug Des. 1995. PMID: 7786399

10

Transfection with human thioredoxin increases cell proliferation and a dominant-negative mutant thioredoxin reverses the transformed phenotype of human breast cancer cells.

Gallegos A, Gasdaska JR, Taylor CW, Paine-Murrieta GD, Goodman D, Gasdaska PY, Berggren M, Briehl MM, Powis G. Gallegos A, et al. Cancer Res. 1996 Dec 15;56(24):5765-70. Cancer Res. 1996. PMID: 8971189

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters